← Back to Search

Behavioural Intervention

CT-100-004-A Psoriasis for Psoriasis

N/A

Waitlist Available

Research Sponsored by Click Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Itch NRS ≥ 4 during screening

Aged 18 years or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 5

Awards & highlights

Study Summary

This trial involves a platform called CT-100 that uses interactive software for therapeutic purposes. One type of component in CT-100 is called Digital Neuro-activation and Modulation (DiNaMo), which

Who is the study for?

This trial is for individuals with skin conditions like atopic dermatitis, eczema, or psoriasis. Participants should be interested in trying a digital intervention aimed at reducing scratching behavior.Check my eligibility

What is being tested?

The study tests two versions of CT-100, a software platform with interactive components designed to disrupt scratching by targeting neural systems related to various sensory and cognitive processes.See study design

What are the potential side effects?

Since this is a digital intervention involving software-based therapeutic components, traditional physical side effects are not expected. Users may experience eye strain or mental fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My itchiness level is 4 or higher.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 5

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 5

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 5 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Dermatology Life Quality Index

Change in Peak Pruritus Numerical Rating Scale

Change in Quality of Life symptoms

+3 more

Secondary outcome measures

Frequency of Adverse Events

Frequency of Serious Adverse Events

Severity of Adverse Events

+1 more

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: CT-100-004-A PsoriasisExperimental Treatment1 Intervention

Group II: CT-100-004-A Atopic DermatitisExperimental Treatment1 Intervention

Group III: CT-100-004-B PsoriasisPlacebo Group1 Intervention

Group IV: CT-100-004-B Atopic DermatitisPlacebo Group1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Click Therapeutics, Inc.Lead Sponsor

15 Previous Clinical Trials

2,847 Total Patients Enrolled

Shaheen LakhanStudy DirectorClick Therapeutics

3 Previous Clinical Trials

343 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available vacancies for potential participants in this research study?

"As per clinicaltrials.gov, this investigation is currently seeking participants. It was initially listed on 12/4/2023 and last revised on 2/16/2024."

Answered by AI

How large is the participant pool for this clinical trial in its entirety?

"Affirmative. Details on clinicaltrials.gov show that recruitment is ongoing for this investigation. The trial was made public on December 4, 2023, with the latest update recorded on February 16, 2024. Enrollment of approximately 120 patients is targeted at a singular site."

Answered by AI

What are the desired results that researchers hope to achieve through this investigation?

"The main focus of this research, assessed from Baseline to Week 4, is enhancing the overall assessment of improvement. Secondary goals encompass monitoring the occurrence and severity of both general adverse events as well as more severe ones throughout the study duration."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

2023. "An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06275659.

All > Psoriasis > Atopic Dermatitis